Navigation Links
Btk in Medical News

Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results

...2009 was primarily due to reduced personnel expenses, reduced manufacturing costs and outside preclinical expenses associated with the company's HDAC, btk and Factor VIIa Inhibitor programs. Pharmacyclics also reported its financial results for the nine months ended March 31, 2009. The net loss for...

Pharmacyclics Reports Third Quarter 2008 Financial Results

...uring expenses associated with the Company's HDAC, btk and Factor VIIa inhibitor programs. Pharmacyclic...applications for our Factor VIIa inhibitor and our btk inhibitor," said Richard A. Miller, M.D., presiden...ns relating to the company's HDAC, Factor VIIa and btk programs were made at the American Association...
Btk in Medical Technology

Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma

SUNNYVALE, Calif., April 13 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced that it has begun treating patients in a Phase 1 dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine ...

Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma

SUNNYVALE, Calif., June 9 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced results from a preclinical study evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in collagen induced arthritis, an established animal mod...

Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases

SAN DIEGO and SUNNYVALE, Calif., April 14 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today presented results from its preclinical program evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in B-cell receptor (BCR) modulated d...

Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.

...ss inhibitor of Bruton's tyrosine kinase (Btk) (PCI-32765) currently in a Phase I clinical trial and targeting B-cell related oncology applications; a btk inhibitor in advanced preclinical testing (PCI-45261) targeting autoimmune and allergic indications; and an HDAC-8 inhibitor (PCI-34051) for autoimmun...

Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Bruton's Tyrosine Kinase Inhibitors

..., researchers tested the effects of Pharmacyclics' btk inhibitor, PCI-31523, on a variety of B cell recep...tion results in uncontrolled B-cell proliferation. btk is a tyrosine kinase inside B-cells that plays an ... role in B-cell activation. Drugs that can inhibit btk may prevent B-cell activation and therefore may pl...
Btk in Biological News

Patients now surviving once-fatal immune disease

...were quite surprised at how well these patients are doing with the proper care." XLA is a rare disease that is inherited through a mutation in the btk gene on the X-chromosome--one of the two types of sex chromosomes. Males with this disease have very low levels of infection-fighting proteins called ...
Btk in Biological Technology

Pharmacyclics, Inc. Rights Offering Oversubscribed

...d autoimmune diseases. With the announcement of today's offering, we have the capital to drive our programs forward, particularly PCI 32765, our novel btk Inhibitor, and PCI 24783, our Factor VIIa Inhibitor, to several inflection points. We are committed to driving shareholder value and look forward to u...

Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results

...reduced personnel expenses due to lower headcount and reduced manufacturing costs and outside preclinical expenses associated with the company's HDAC, btk and Factor VIIa inhibitor programs. Pharmacyclics also reported its financial results for the six months ended December 31, 2008. The net loss...

Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results

...reduced personnel expenses due to lower headcount and reduced manufacturing costs and outside preclinical expenses associated with the company's HDAC, btk and Factor VIIa inhibitor programs. As of September 30, 2008, the company's cash, cash equivalents and marketable securities totaled $12.5 million c...

Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results

...nteers with our Factor VIIa inhibitor, PCI-27483, in the fourth quarter of calendar 2008. * Plan to initiate a Phase 1 trial with our oral btk inhibitor, PCI-32765, in patients with recurrent B-cell lymphoma in the fourth quarter of calendar 2008. This study is designed to eval...

Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting

...ter presentation: Levels of tonic BCR signaling predict response to the btk inhibitor PCI-32765 Abstract #2396: 8:00 a.m. - 12:00 p.m. Presente...ata on our HDAC inhibitor, other presentations describe our Factor VIIa and btk inhibitors, which we anticipate will enter clinical testing later this year...
Btk in Biological Definition

Oncogene

...ceptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), etc. Cytoplasmic tyrosine kinases like the Src-family, Syk-ZAP-70 family and btk family of tyrosine kinases. Regulatory GTPases , for example, the Ras protein . Cytoplasmic Serine / Threonine kinases and their regula...
Other Tags
(Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International ... after an 8 year battle with breast cancer. ... in her home in Woodland Hills California after an ... , As the founder and volunteer President ... and championed many of today's greatest breakthroughs in restoring ...
(Date:12/25/2014)... 25, 2014 Recently, LunaDress.co.uk has updated its blog ... related accessories. Now, all of the models at LunaDress.co.uk come with ... groom lifts the wedding veil can turn out to be a ... A wedding veil can always bring surprise to a wedding. On ... how to choose veils for a big day . , ...
(Date:12/25/2014)... (HealthDay News) -- The risk of burns from fires ... need to be extra cautious, an expert says. ... significant increase in patients coming in with burns," said ... Volunteer Firefighters Burn Center of Stony Brook University Hospital ... of joy, but if not careful, could quickly turn ...
(Date:12/25/2014)... News) -- Among early stage breast cancer patients who ... one percent will eventually develop leukemia as a result ... finding comes from a review of more than 20,000 ... it suggests that the risk for developing treatment-related leukemia, ... thought. "The frequency of bone marrow cancers such ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
Other Contents